IP Library › Granted Patent US 7,993,922
Granted Patent B2
US 7,993,922 · App. 11/976,960 · Granted Aug 9, 2011

Three-dimensional tissue equivalent using macromass culture

Assignee: Reliance Life Sciences Pvt. Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,993,922
App. No.
11/976,960
Granted
Aug 9, 2011
Kind
B2
Abstract

The present invention provides a three-dimensional tissue equivalent for in-vivo and in-vitro uses. The three dimensional tissue equivalent of the present invention is a non-contractile cellular sheet cultured over a porous scaffold using a macromass culturing technique, for example where the cellular sheet is entirely on one side of a porous sponge. In one embodiment, the present invention provides a dermal wound dressing that comprises a high density cellular sheet of dermal fibroblast cells.

Claims (12)

1. A process for preparing a three dimensional non-contractile tissue equivalent comprising a macromass cellular sheet of dermal fibroblast cells adhered to a porous scaffold or matrix, wherein the method comprises:

a) absorbing a liquid blocking agent into pores of the porous scaffold or matrix,

b) solidifying the blocking agent;

c) culturing dermal fibroblast cells onto only one side of the porous scaffold or matrix to form a multilayered high density macromass cellular sheet, wherein the porous scaffold or matrix comprises pores that do not contact the macromass cellular sheet and are devoid of the cells;

d) desolidifying and removing the blocking agent; and

e) forming a three dimensional non-contractile tissue equivalent comprising the macromass cellular sheet adhered to the porous scaffold or matrix.

2. The method of claim 1 , wherein the dermal fibroblast cells comprise neonatal human dermal fibroblast cells.

3. The method of claim 1 , wherein the blocking agent comprises material chosen from gelatin, alginate, pectin, agar and agarose.

4. The method of claim 1 , wherein the porous scaffold or matrix comprises material chosen from chitosan, collagen, polyglycolic acid, and polylactic acid.

5. The method of claim 1 , wherein the dermal fibroblast cells do not leak or pass through the pores of the porous scaffold or matrix during the culturing step.

6. The method of claim 1 , wherein at least 20×10 6 dermal fibroblast cells are seeded onto the porous scaffold or matrix during the culturing step, and wherein the macromass cellular sheet has a cell density of 1×10 6 cells per cm 2 to 12×10 6 cells per cm 2 of the porous scaffold or matrix.

7. The method of claim 1 , wherein the cells in the macromass cellular sheet express VEGF and/or IL-8 in an amount greater than would be expressed by the same cells in a monolayer having the same diameter as the macromass cellular sheet.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 7, 2008
From: DESHPANDE, MANISHA SHARADCHANDRA; RAO, SITHAMRAJU HARINARAYANA; WANGIKAR, PRALHAD BALASAHEB; KUCHROO, PUSHPA VIKRAM
To: RELIANCE LIFE SCIENCES PVT. LTD.
Reel/Frame 021675/0336 →
Priority Claims (1)
IN 912/MUM/2002 · Oct 18, 2002 · national
Continuity (2)
Continuation In Part 10686822 · Oct 16, 2003
Related Publication 20080145344A1 · Jun 19, 2008